Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

AUROPHARMA's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.850000
forwardPE 14.551872
debtToEquity 25.310000
earningsGrowth 0.003000
revenueGrowth 0.106000
grossMargins 0.589380
operatingMargins 0.160760
trailingEps 59.800000
forwardEps 62.290000

AUROPHARMA's current ratio of 1.85 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that AUROPHARMA is financially well-prepared to meet its liabilities without difficulty.
Aurobindo Pharma Limited's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
AUROPHARMA's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests AUROPHARMA maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
AUROPHARMA's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that AUROPHARMA is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

The gradual downward revision of Aurobindo Pharma Limited's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about Aurobindo Pharma Limited's growth potential.

Insider Transactions:

Insider Transactions for AUROPHARMA
Insider Transactions for AUROPHARMA


1 sales transactions of Aurobindo Pharma Limited were conducted, with market price at 1019.8499755859375.No sell transactions took place in the period under consideration.The trend of more buys compared to sells around AUROPHARMA's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


AUROPHARMA has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view AUROPHARMA as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.